Increased plasma urotensin II levels in patients with diabetes mellitus

被引:161
作者
Totsune, K
Takahashi, K
Arihara, Z
Sone, M
Ito, S
Murakami, O
机构
[1] Tohoku Univ, Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Sch Med, Dept Mol Biol & Appl Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan
关键词
diabetes; plasma; reverse transcriptase-PCR; RIA; urotensin II; vascular endothelial cell;
D O I
10.1042/CS20020271
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Urotensin II (UII) is the most potent vasoconstrictor peptide, whereas it acts as a vasodilator on some arteries. We studied plasma levels of UII in diabetic patients with normal serum creatinine levels (< 90 mu mol/l) and the expression of UII and its receptor in cultured human vascular endothelial cells. Plasma UII levels were significantly elevated by 1.8-fold in diabetic patients without proteinuria (7.8+/-0.6 fmol/ml; P < 0.0001) and 1.7-fold in those with overt proteinuria (7.3+/-0.9 fmol/ml; P = 0.0018) when compared with healthy subjects (4.4+/-0.2 fmol/ml). No significant correlation was obtained between plasma UII levels and fasting blood sugar (P = 0.631 and P = 0.853 in non-proteinuric and proteinuric diabetic patients respectively), glycated haemoglobin levels (P = 0.376 and P = 0.888 respectively) or serum creatinine levels (P = 0.301 and P = 0.568 respectively). Reverse transcriptase-PCR analysis showed the expression of mRNAs encoding UII precursor and UII-receptor precursors in cultured human coronary artery endothelial cells and umbilical vein endothelial cells, suggesting that vascular endothelial cells are one of the sources of UII in blood. These findings suggest that elevation of plasma UII levels may be an important background factor in diabetic cardiovascular and organ complications in diabetic subjects without renal failure.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 25 条
[1]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[2]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[3]   Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease [J].
Bolger, AP ;
Sharma, R ;
Li, W ;
Leenarts, M ;
Kalra, PR ;
Kemp, M ;
Coats, AJS ;
Anker, SD ;
Gatzoulis, MA .
CIRCULATION, 2002, 106 (01) :92-99
[4]   Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries [J].
Bottrill, FE ;
Douglas, SA ;
Hiley, CR ;
White, R .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (08) :1865-1870
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy [J].
Cooper, ME .
DIABETOLOGIA, 2001, 44 (11) :1957-1972
[7]   Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord [J].
Coulouarn, Y ;
Lihrmann, I ;
Jegou, S ;
Anouar, Y ;
Tostivint, H ;
Beauvillain, JC ;
Conlon, JM ;
Bern, HA ;
Vaudry, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15803-15808
[8]   Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey [J].
Douglas, SA ;
Sulpizio, AC ;
Piercy, V ;
Sarau, HM ;
Ames, RS ;
Aiyar, NV ;
Ohlstein, EH ;
Willette, RN .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) :1262-1274
[9]  
Guerci B, 2001, DIABETES METAB, V27, P425
[10]   Plasma adrenomedullin in diabetes [J].
Hayashi, M ;
Shimosawa, T ;
Isaka, M ;
Yamada, S ;
Fujita, R ;
Fujita, T .
LANCET, 1997, 350 (9089) :1449-1450